GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination of tetrahydrocannabinol …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) hosted an analyst meeting last night at the American Epilepsy Society (AES) meeting that was met with marked …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares are on a 6% ascent today after the biotech firm presented additional Epidiolex data from the first …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announces results from two completed Epidiolex® (cannabidiol or CBD) Phase 3 trials, one in Lennox-Gastaut syndrome (LGS) and …
Joshua Schimmer at Piper Jaffray is chiming in on two biotech players, Gilead Sciences, Inc. (NASDAQ:GILD) and GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), in …
In a research report released on Friday, Goldman Sachs top analyst Salveen Richter initiated coverage on shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) with a …
Yesterday morning, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announced the success of its second Lennox-Gastaut Syndrome Phase III trial, evaluating pipeline drug Epidiolex, the …
It is a day full of great news for the biotech-verse as Array Biopharma Inc (NASDAQ:ARRY) shares are shooting 54% today on back …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) investors cheer the announcement that the drug maker achieved positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial …
